Navigation Links
Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009
Date:2/17/2009

    DUSSELDORF, Germany, February 17 /PRNewswire/ --

    - Sales Grow by 10.7% to EUR1.06bn

    - Adjusted Earnings per Share Improves by 36.6% From EUR1.34 Euro to
      EUR1.83

    - Adjusted EBITDA Margin Rises From 19.0 to 19.5%

    - CEO Dr. Axel Herberg: "Following the record year in 2008 Gerresheimer
      again considers itself well equipped to meet the global challenges in
      2009 and is aiming for further substantial sales growth of 6% to 7% in
      the core business."

In 2008 Gerresheimer AG had another record year marked by important milestones, and achieved all its published objectives. The international Group with its main base in Dusseldorf, Germany, increased its sales by 10.7% (12.8% on a like-for-like exchange-rate basis) and thereby passed the billion euro mark. Operating results (Adjusted EBITDA) rose by 13.7% to EUR206.4m (prior year: EUR181.6m). The Adjusted EBITDA margin reached 19.5% in 2008 (prior year: 19%). There was a substantial improvement of 36.6% in adjusted earnings per share in the past financial year to EUR1.83 (prior year EUR1.34).

"Our strategy of internationalization and focus is bearing fruit," says Dr. Axel Herberg, CEO of Gerres-heimer AG. "Even in a phase of worldwide economic downturn, pharmaceutics and life science are still growth markets and, with its broad technology base and worldwide presence, Gerresheimer has a strong position here." The shareholders of Gerresheimer AG should participate in the success of Gerresheimer AG as in the prior year. The Management Board and Supervisory Board of Gerresheimer AG will therefore propose to the Shareholders' Meeting that a dividend of EUR0.40 per share is paid.

In December 2008, Gerresheimer AG was included in the second-largest German selection index MDax. This means increased visibility for our company on capital markets, and greater appeal for our shares.

Further substantial growth for pharma & life science

All the divisions of Gerresheimer AG participated in the substantial sales growth achieved in the past financial year. The business in the pharma & life science markets proved to be particularly stable and high-growth, and today already represents 75% (prior year: 72%) of Gerresheimer's total sales. The continuing high level of demand for RTF(C) syringe systems, which grew by 36% in 2008, made a decisive contribution to this. Another growth contributor was the business in plastic systems, which today accounts for around 32% of the total sales of Gerresheimer AG. In this Division there was particularly strong demand for inhalers for asthma treatment and products for diabetes diagnosis and treatment.

Extensive investment in growth markets

In order to secure future growth in its core pharmaceutical markets Gerresheimer AG invested extensively during the financial year 2008 in capacity expansion programs and new projects such as, for example, the construction of a third facility for RTF(R) syringe production and the build-up of production of insulin pen systems. Investments in capital assets (including intangible assets) during the past financial year totaled EUR107.8m (prior year: EUR98.9m).

Continued focus on internationalization and a wider product range

An important success factor for Gerresheimer AG has been - and continues to be - the consistently implemented strategy of internationalization and focus. In 2008 Gerresheimer again expanded its global presence and thereby also widened its product range. The Brazilian manufacturer of pharmaceutical plastic packaging Allplas (now Gerresheimer Plasticos Sao Paulo Ltda.) and the Spanish company EDP (now Gerresheimer Zaragoza S.A.) which were taken over at the beginning of 2008 were successfully integrated in the Gerresheimer Group during the year. Both companies rank among the market leaders in their region and have already made a positive contribution in 2008 to the development of our Plastic Systems Division.

In the course of concentration on the pharma & life science markets, further steps were taken in the financial year 2008. In June 2008 Gerresheimer discontinued its Consumer Healthcare business.

Outlook for 2009

Gerresheimer will continue its successful international course in the financial year 2009 and, despite the generally challenging economic situation, is confident that it can achieve its growth targets: "After the record year in 2008, Gerresheimer AG is well positioned for the global challenges in 2009, and is aiming for further substantial growth," says the CEO Dr. Axel Herberg. For 2009, sales growth of 6% to 7% is expected in the core business, with an adjusted-EBITDA margin of 19.0% to 19.2%. The core business does not include the Technical Plastics business, for which sales of EUR35-45m are expected in 2009.

About Gerresheimer

Gerresheimer employs 10,200 people in 42 locations in Europe, America and Asia. In the financial year 2009, worldwide sales totalled EUR1.06bn. The product portfolio ranges from pharmaceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterised by high technical and regulatory barriers.

    Group Key Figures (IFRS; Financial Year end November 30)

    in EUR million                 FY 2008  FY 2007 Change %

    Net sales                       1060.1    957.7    +10.7
    Adjusted EBITDA(1)               206.4    181.6    +13.7
    in % of net sales                 19.5     19.0
    Adjusted EBITA                   135.6    116.6    +16.3
    in % of net sales                 12.8     12.2
    Profit from operations (EBIT)     61.0     53.3    +14.4
    Net income                         4.5      0.8     >100
    Adjusted net income(2)            61.4     44.3    +38.6
    Earnings per share in EUR         0.02    -0.04     >100
    Adjusted earnings per             1.83     1.34    +36.6
    share(3) in EUR



    ---------------------------------

    (1) Adjusted EBITDA: earnings before income taxes, financial result,
        amortization of fair value adjustments, extraordinary depreciation,
        depreciation and amortization, restructuring expenses and one-off
        income and expenses

    (2) Adjusted net income: consolidated profit before non-cash amortization
        of fair value adjustments, special effects from restructuring
        expenses, extraordinary depreciation, the balance of one-off income
        and expenses (including significant non-cash expenses) and the
        related tax effects

    (3) Adjusted net income after minorities divided by 31.4m shares



    Contact Press
    Burkhard Lingenberg
    Director Corporate Communication & Marketing
    Phone +49-211-6181-250
    Fax +49-211-6181-241
    e-mail b.lingenberg@gerresheimer.com

    Contact Investor Relations
    Anke Linnartz
    Director Corporate Investor Relations
    Phone +49-211-6181-314
    Fax +49-211-6181-121
    e-mail a.linnartz@gerresheimer.com


'/>"/>
SOURCE Gerresheimer AG
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
3. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
4. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
5. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
6. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
7. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
8. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
9. ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
10. Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
11. Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)...   BioInformant announces the February 2016 release ... Opportunities, Tools, and Technologies – Market Size, Segments, Trends, ... The first and only market ... BioInformant has more than a decade of historical information ... stem cell type. This powerful 175 page global strategic ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... cell treatment clinic in Quito, Ecuador. The new facility will provide advanced protocols ... patients from around the world. , The new GSCG clinic is headed ...
(Date:2/10/2016)... Feb. 10, 2016  The Maryland House of Delegates ... announced that University of Maryland School of Medicine Dean ... University of Maryland Medical System President and CEO ... Medallion," the highest honor given to the public by ... Dean Reece and Mr. Chrencik for their ...
(Date:2/10/2016)... New York, and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it ... and develop new vaccines and immunotherapies for infectious diseases and cancer. ...
Breaking Biology Technology:
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first ... (AHA) announced plans to develop a first of its ... power of IBM Watson. In the first application of ... IBM (NYSE: IBM ), and Welltok will create ... health assessments with cognitive analytics, delivered on Welltok,s health ...
(Date:1/25/2016)... 25, 2016  Glencoe Software, the world-leading supplier of ... industries, will provide the data management solution OMERO Plus ... Photo - ... Phenotypic analysis measures the characteristics and ... comparisons between states such as health and disease, the ...
(Date:1/20/2016)... 20, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce the attainment ... are the result of the company,s laser focus on ... , it,s comprehensive, easy-to-use and highly affordable cloud-based ... Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):